Zolbetuximab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric |
Target | CLDN18.2 |
Clinical data | |
Other names | IMAB362; Claudiximab |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
(what is this?) (verify) |
Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.[1]
The drug is in phase III clinical trials as of November 2021.[2]
Preliminary results from the phase II 'FAST' trial in June 2016 suggest it is helpful for advanced gastric cancer.[3]
References
- ↑ "Our mission - Ganymed Pharmaceuticals GmbH - Ganymed Pharmaceuticals GmbH". www.ganymed-pharmaceuticals.de.
- ↑ "A Study of Zolbetuximab (IMAB362)". clinicaltrials.gov. 19 November 2021.
- ↑ "Antibody Shines in Advanced Gastric Cancer". medpagetoday.com. 5 June 2016.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.